Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free PCRX Stock Alerts

Pacira BioSciences (PCRX) Short Interest Ratio & Short Volume

Pacira BioSciences logo
$25.88 -0.05 (-0.19%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$25.90 +0.02 (+0.08%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Pacira BioSciences Short Interest Overview

As of July 15, 2026, Pacira BioSciences (PCRX) had a short interest of 6.96 million shares sold short, representing 18.91% of the public float. This marks a 5.70% increase in short interest since the prior report. The short interest ratio (days to cover) is 15.8, meaning it would take 15.8 days of the average trading volume of 498,680 shares to cover all short positions.

Current Short Interest
6,963,375 shares
Previous Short Interest
6,587,848 shares
Change Vs. Previous Month
5.70%
Dollar Volume Sold Short
$176.38 million
Short Interest Ratio
15.8 Days to Cover
Last Record Date
July 15, 2026
Outstanding Shares
39,350,000 shares
Short Percent of Float
18.91%
Today's Trading Volume
425,447 shares
Average Trading Volume
498,680 shares
Today's Volume Vs. Average
85%
Short Selling Pacira BioSciences?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Pacira BioSciences and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

PCRX Short Interest Over Time

PCRX Days to Cover Over Time

PCRX Percentage of Float Shorted Over Time

Pacira BioSciences Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
7/15/20266,963,375 shares $176.38 million +5.7%18.9%15.78 $25.33
6/30/20266,587,848 shares $167.13 million +5.0%17.9%11.65 $25.37
6/15/20266,276,888 shares $142.74 million -4.8%17.0%16.69 $22.74
5/29/20266,596,044 shares $153.16 million -5.6%17.9%14.06 $23.22
5/15/20266,987,520 shares $158.20 million -10.3%19.0%10.27 $22.64
4/30/20267,790,589 shares $198.58 million +5.4%21.2%14.23 $25.49
4/15/20267,391,141 shares $173.17 million -8.3%20.1%15.7 $23.43
3/31/20268,059,032 shares $182.13 million -4.6%21.3%10.12 $22.60
3/13/20268,448,571 shares $196.51 million -0.3%22.3%10.07 $23.26
2/27/20268,474,359 shares $185.67 million +10.3%22.4%9.25 $21.91
2/13/20267,684,573 shares $167.29 million -2.5%20.9%10.91 $21.77
1/30/20267,881,129 shares $161.88 million +10.8%19.6%8.4 $20.54
1/15/20267,111,947 shares $146.86 million -3.3%17.7%6.11 $20.65
12/31/20257,357,458 shares $190.41 million +0.2%18.3%9.06 $25.88
12/15/20257,343,873 shares $195.93 million +1.7%18.2%8.79 $26.68
11/28/20257,220,261 shares $192.64 million -0.8%17.9%10.75 $26.68
11/14/20257,276,394 shares $173.03 million -0.1%17.3%8.05 $23.78
10/31/20257,282,190 shares $155.69 million +22.5%17.3%13.28 $21.38
10/15/20255,950,000 shares $139.53 million -5.3%13.6%9.2 $23.45
9/30/20256,280,000 shares $161.84 million -6.1%14.4%9.7 $25.77
9/15/20256,690,000 shares $179.69 million +1.2%15.3%10.2 $26.86
8/31/20256,610,000 shares $176.29 million +5.1%15.5%10.1 $26.67
8/15/20256,290,000 shares $155.87 million +10.5%14.7%10 $24.78
7/31/20255,690,000 shares $120.00 million +4.2%13.3%7.9 $21.09
7/15/20255,460,000 shares $124.11 million -2.5%N/A8 $22.73
6/30/20255,600,000 shares $133.84 million No Change12.9%7.1 $23.90
6/15/20255,600,000 shares $135.74 million -4.0%12.9%6.7 $24.24
5/31/20255,830,000 shares $150.36 million +2.6%13.5%6.6 $25.79
5/15/20255,680,000 shares $145.41 million -7.6%13.1%5.9 $25.60
4/30/20256,150,000 shares $165.44 million +1.5%N/A6.8 $26.90
4/15/20256,060,000 shares $150.77 million +2.2%14.0%6.6 $24.88
3/31/20255,930,000 shares $147.36 million No Change13.7%6.4 $24.85
3/15/20255,930,000 shares $135.62 million +1.2%13.7%6.9 $22.87
2/28/20255,860,000 shares $140.93 million +10.6%13.6%6.8 $24.05
2/15/20255,300,000 shares $134.83 million +3.1%12.3%6.5 $25.44
1/31/20255,140,000 shares $135.34 million -5.5%N/A6.4 $26.33
1/15/20255,440,000 shares $119.03 million +24.8%N/A7.4 $21.88
12/31/20244,360,000 shares $82.14 million -8.2%N/A6.4 $18.84
12/15/20244,750,000 shares $94.34 million -1.0%N/A6.6 $19.86
11/30/20244,800,000 shares $81.17 million -0.4%N/A6 $16.91
Iran War Shock: What I Was Told In That Private Meeting (Ad)

You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel

Because THIS is the real reason.
11/15/20244,820,000 shares $80.01 million -11.7%N/A6.2 $16.60
10/31/20245,460,000 shares $90.64 million -11.1%N/A5.3 $16.60
10/15/20246,140,000 shares $102.48 million -2.7%N/A5.3 $16.69
9/30/20246,310,000 shares $94.97 million +9.7%N/A5 $15.05
9/15/20245,750,000 shares $75.38 million -5.0%N/A4 $13.11
8/31/20246,050,000 shares $94.14 million +17.5%N/A4.5 $15.56
8/15/20245,150,000 shares $68.75 million -18.4%N/A4 $13.35
7/31/20246,310,000 shares $130.30 million -2.9%N/A5.3 $20.65
7/15/20246,500,000 shares $138.45 million -3.4%N/A6.2 $21.30
6/30/20246,730,000 shares $192.55 million +5.8%N/A7.2 $28.61
6/15/20246,360,000 shares $178.91 million -1.1%N/A8.8 $28.13
5/31/20246,430,000 shares $195.02 million +6.5%N/A9.9 $30.33
5/15/20246,040,000 shares $181.68 million +67.8%N/A9.4 $30.08
4/30/20243,600,000 shares $94.50 million +4.4%N/A6.7 $26.25
4/15/20243,450,000 shares $91.53 million -7.8%N/A7 $26.53
3/31/20243,740,000 shares $109.28 million -8.1%N/A7.5 $29.22
3/15/20244,070,000 shares $119.70 million -2.4%N/A8.1 $29.41
2/29/20244,170,000 shares $123.93 million +5.8%N/A7.4 $29.72
2/15/20243,940,000 shares $116.86 million +1.0%N/A7.4 $29.66
1/31/20243,900,000 shares $127.10 million +4.6%N/A6.9 $32.59
1/15/20243,730,000 shares $120.18 million +6.9%N/A7 $32.22
12/31/20233,490,000 shares $117.75 million +7.4%N/A6.5 $33.74
12/15/20233,250,000 shares $101.69 million -0.9%N/A5.8 $31.29
11/30/20233,280,000 shares $89.48 million +2.8%N/A6.7 $27.28
11/15/20233,190,000 shares $91.11 million -11.1%N/A6.4 $28.56
10/31/20233,590,000 shares $101.45 million -8.7%N/A7.5 $28.26
10/15/20233,930,000 shares $114.52 million +12.0%N/A7.7 $29.14
9/30/20233,510,000 shares $107.69 million -0.3%N/A6.5 $30.68
9/15/20233,520,000 shares $118.41 million -1.4%N/A6.8 $33.64
8/31/20233,570,000 shares $126.02 million -4.8%N/A6.3 $35.30
8/15/20233,750,000 shares $139.91 million +9.7%N/A6.6 $37.31
7/31/20233,420,000 shares $124.32 million -3.4%N/A5.9 $36.35
7/15/20233,540,000 shares $132.01 million -2.5%N/A6 $37.29
6/30/20233,630,000 shares $145.45 million -0.6%N/A6.3 $40.07
6/15/20233,650,000 shares $147.17 million +3.7%N/A6.6 $40.32
5/31/20233,520,000 shares $133.87 million +4.5%N/A6.6 $38.03
5/15/20233,370,000 shares $143.12 million +7.7%N/A5.9 $42.47
4/30/20233,130,000 shares $141.82 million +4.0%N/A5.4 $45.31
4/15/20233,010,000 shares $127.77 million No ChangeN/A5.5 $42.45
3/31/20233,010,000 shares $122.84 million -10.4%N/A5.6 $40.81
3/15/20233,360,000 shares $132.25 million -5.9%N/A6.1 $39.36
2/28/20233,570,000 shares $151.97 million No ChangeN/A6.1 $42.57
2/15/20233,570,000 shares $144.91 million -20.7%N/A6.6 $40.59
1/31/20234,500,000 shares $176.72 million -12.8%N/A8.6 $39.27
1/15/20235,160,000 shares $193.09 million +4.2%N/A9.9 $37.42
12/30/20224,950,000 shares $191.12 million +7.1%N/A9.9 $38.61
12/15/20224,620,000 shares $184.38 million -6.3%N/A10.1 $39.91
11/30/20224,930,000 shares $237.87 million -10.5%N/A12.6 $48.25
11/15/20225,510,000 shares $275.50 million +0.7%N/A14.4 $50.00
10/31/20225,470,000 shares $283.13 million +1.7%N/A15.3 $51.76
A letter from Shannon Stansberry (Ad)

Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel

Watch the full story and see the verified track record for yourself
10/15/20225,380,000 shares $277.61 million +4.3%N/A15.3 $51.60
9/30/20225,160,000 shares $274.46 million +2.2%N/A13.9 $53.19
9/15/20225,050,000 shares $274.06 million +4.3%N/A12.7 $54.27
8/31/20224,840,000 shares $254.00 million +3.9%N/A11.3 $52.48
8/15/20224,660,000 shares $269.02 million +1.8%N/A10.7 $57.73
7/31/20224,580,000 shares $259.04 million -0.2%N/A9.7 $56.56
7/15/20224,590,000 shares $252.45 million +5.8%N/A9.2 $55.00
6/30/20224,340,000 shares $253.02 million -12.9%N/A8.3 $58.30
6/15/20224,980,000 shares $271.66 million -3.1%12.5%9.4 $54.55
5/31/20225,140,000 shares $325.11 million +0.2%N/A9.9 $63.25
5/15/20225,130,000 shares $315.75 million -3.9%N/A9.2 $61.55
4/30/20225,340,000 shares $398.20 million +3.5%N/A9.5 $74.57
4/15/20225,160,000 shares $385.35 million -8.0%11.8%9.3 $74.68
3/31/20225,610,000 shares $428.16 million -3.3%12.9%10.3 $76.32
3/15/20225,800,000 shares $409.42 million -7.9%13.3%11.6 $70.59
2/28/20226,300,000 shares $420.15 million -4.8%14.4%12 $66.69
2/15/20226,620,000 shares $428.58 million -1.1%15.3%13.3 $64.74
1/31/20226,690,000 shares $419.93 million +5.2%15.4%13.5 $62.77
1/15/20226,360,000 shares $407.55 million -6.5%14.7%13.2 $64.08
12/31/20216,800,000 shares $409.16 million -0.2%15.7%14.5 $60.17
12/15/20216,810,000 shares $392.05 million -0.7%15.7%13.1 $57.57
11/30/20216,860,000 shares $360.97 million +4.9%15.8%13.8 $52.62
11/15/20216,540,000 shares $366.17 million -3.8%15.1%14.3 $55.99
10/29/20216,800,000 shares $355.50 million +3.8%15.7%15 $52.28
10/15/20216,550,000 shares $348.46 million -5.4%15.1%14.8 $53.20
9/30/20216,920,000 shares $387.52 million -3.4%16.0%16.4 $56.00
9/15/20217,160,000 shares $395.09 million +5.6%16.5%20.6 $55.18
8/31/20216,780,000 shares $401.99 million +1.8%15.6%17.6 $59.29
8/13/20216,660,000 shares $388.41 million -1.3%15.4%17 $58.32
7/30/20216,750,000 shares $397.91 million -2.7%15.6%16.1 $58.95

PCRX Short Interest - Frequently Asked Questions

Short interest is the volume of Pacira BioSciences shares that have been sold short but have not yet been covered or closed out. As of July 15th, investors have sold 6,963,375 shares of PCRX short. 18.91% of Pacira BioSciences' shares are currently sold short. Learn More on Pacira BioSciences' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PCRX shares currently have a short interest ratio of 15.8. Learn More on Pacira BioSciences's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 18.91% of Pacira BioSciences' floating shares are currently sold short.

Pacira BioSciences saw a increase in short interest in July. As of July 15th, there was short interest totaling 6,963,375 shares, an increase of 5.7% from the previous total of 6,587,848 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

18.91% of Pacira BioSciences' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Pacira BioSciences: Supernus Pharmaceuticals, Inc. (9.13%), Nektar Therapeutics (20.70%), Perrigo Company plc (16.64%), Omeros Corporation (23.30%), Assembly Biosciences, Inc. (15.08%), Eli Lilly and Company (1.09%), Johnson & Johnson (1.14%), AbbVie Inc. (1.28%), Merck & Co., Inc. (1.19%), Pfizer Inc. (2.89%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($73.09 billion), Invesco QQQ ($48.11 billion), iShares Russell 2000 ETF ($23.61 billion), Sandisk Corporation ($12.69 billion), Nebius Group N.V. ($12.18 billion), Western Digital Corporation ($11.95 billion), SPDR S&P Biotech ETF ($11.73 billion), Quhuo Limited Sponsored ADR ($9.74 billion), VanEck Semiconductor ETF ($9.57 billion), and Financial Select Sector SPDR Fund ($8.43 billion). View all of the most shorted stocks.

Short selling PCRX is an investing strategy that aims to generate trading profit from Pacira BioSciences as its price is falling. PCRX shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Pacira BioSciences occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PCRX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PCRX, twice per month. The most recent reporting period available is July, 15 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like PCRX:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NASDAQ:PCRX) was last updated on 7/24/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
Buy this stock tomorrow
Marc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...
Chaikin Analytics | Sponsoredtc pixel
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely | Sponsoredtc pixel
He Called NVIDIA at $1.10 – Now He Says, “SELL”
The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...
The Oxford Club | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel